1
|
Iwańczyk S, Bujak K, Wolny R, Janas A, Dziarmaga M, Opolski MP, Januszek R, Włodarczak A, Desperak P, Niezgoda P, Kryjak M, Tomaniak M, Huczek Z, Hawranek M, Cortese B, Wańha W. Are we at dawn of the drug-coated balloons era? Current evidence, future directions, and tasks of the newly established working group of the Association of Cardiovascular Interventions. Cardiol J 2024; 31:507-511. [PMID: 39212183 PMCID: PMC11374319 DOI: 10.5603/cj.98927] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2024] [Revised: 05/07/2024] [Accepted: 06/05/2024] [Indexed: 09/04/2024] Open
Affiliation(s)
- Sylwia Iwańczyk
- 1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland
- DCB Academy, Milano, Italy
| | - Kamil Bujak
- 3rd Department of Cardiology, Silesian Center for Hear t Disease, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Zabrze, P oland
| | - Rafał Wolny
- Department of Interventional Cardiology and Angiology, National Institute of Cardiology, Warsaw, Poland
| | - Adam Janas
- American Heart of Poland, Center of Cardiovascular Research and Development, Poland
- Division of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland
| | - Miłosz Dziarmaga
- Department of Cardiology-Intensive Therapy, Poznan University of Medical Sciences, Poznan, Poland
| | - Maksymilian P Opolski
- Department of Interventional Cardiology and Angiology, National Institute of Cardiology, Warsaw, Poland
| | - Rafał Januszek
- Department of Cardiology, Jagiellonian University Medical College, Krakow, Poland
| | - Adrian Włodarczak
- Faculty of Health Science and Physical Culture, Witelon Collegium State University, Legnica, Poland
- Department of Cardiology, The Copper Health Centre (MCZ), Lubin, Poland
| | - Piotr Desperak
- Department of Cardiology, Public Clinical Hospital, Rybnik, Poland
| | - Piotr Niezgoda
- Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
| | | | - Mariusz Tomaniak
- First Department of Cardiology, Medical University of Warsaw, Poland
| | - Zenon Huczek
- First Department of Cardiology, Medical University of Warsaw, Poland
| | - Michał Hawranek
- 3rd Department of Cardiology, Silesian Center for Hear t Disease, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Zabrze, P oland
| | - Bernardo Cortese
- DCB Academy, Milano, Italy
- Fondazione Ricerca e Innovazione Cardiovascolare, Milano, Italy
| | - Wojciech Wańha
- DCB Academy, Milano, Italy.
- Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland.
| |
Collapse
|
2
|
Muramatsu T, Kozuma K, Tanabe K, Morino Y, Ako J, Nakamura S, Yamaji K, Kohsaka S, Amano T, Kobayashi Y, Ikari Y, Kadota K, Nakamura M. Clinical expert consensus document on drug-coated balloon for coronary artery disease from the Japanese Association of Cardiovascular Intervention and Therapeutics. Cardiovasc Interv Ther 2023; 38:166-176. [PMID: 36847902 PMCID: PMC10020262 DOI: 10.1007/s12928-023-00921-2] [Citation(s) in RCA: 27] [Impact Index Per Article: 27.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2023] [Accepted: 02/14/2023] [Indexed: 03/01/2023]
Abstract
Drug-coated balloon (DCB) technology was developed to deliver the antiproliferative drugs to the vessel wall without leaving any permanent prosthesis or durable polymers. The absence of foreign material can reduce the risk of very late stent failure, improve the ability to perform bypass-graft surgery, and reduce the need for long-term dual antiplatelet therapy, potentially reducing associated bleeding complications. The DCB technology, like the bioresorbable scaffolds, is expected to be a therapeutic approach that facilitates the "leave nothing behind" strategy. Although newer generation drug-eluting stents are the most common therapeutic strategy in modern percutaneous coronary interventions, the use of DCB is steadily increasing in Japan. Currently, the DCB is only indicated for treatment of in-stent restenosis or small vessel lesions (< 3.0 mm), but potential expansion for larger vessels (≥ 3.0 mm) may hasten its use in a wider range of lesions or patients with obstructive coronary artery disease. The task force of the Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT) was convened to describe the expert consensus on DCBs. This document aims to summarize its concept, current clinical evidence, possible indications, technical considerations, and future perspectives.
Collapse
Affiliation(s)
- Takashi Muramatsu
- Department of Cardiology, Cardiovascular Center, Fujita Health University Hospital, 1-98 Dengaku, Kutsukake, Toyoake, Aichi, 470-1192, Japan.
| | - Ken Kozuma
- Division of Cardiology, Teikyo University Hospital, Tokyo, Japan
| | - Kengo Tanabe
- Division of Cardiology, Mitsui Memorial Hospital, Tokyo, Japan
| | - Yoshihiro Morino
- Division of Cardiology, Department of Internal Medicine, Iwate Medical University, Iwate, Japan
| | - Junya Ako
- Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan
| | | | - Kyohei Yamaji
- Department of Cardiovascular Medicine, Kyoto University, Kyoto, Japan
| | - Shun Kohsaka
- Department of Cardiology, Keio University School of Medicine, Tokyo, Japan
| | - Tetsuya Amano
- Department of Cardiology, Aichi Medical University, Nagakute, Japan
| | - Yoshio Kobayashi
- Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan
| | - Yuji Ikari
- Department of Cardiology, Tokai University School of Medicine, Isehara, Japan
| | - Kazushige Kadota
- Department of Cardiovascular Medicine, Kurashiki Central Hospital, Kurashiki, Japan
| | - Masato Nakamura
- Division of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo, Japan
| | | |
Collapse
|
3
|
Murasato Y. How Should We Select 1- or 2-Stenting According to Coronary Bifurcation Lesion Complexity? Circ J 2022; 86:1376-1378. [DOI: 10.1253/circj.cj-22-0426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Yoshinobu Murasato
- Department of Cardiology and Clinical Research Institute, National Hospital Organization Kyushu Medical Center
| |
Collapse
|